Sol-Gel Technologies (SLGL +1.6%) has consummated its seventh collaboration agreement with Perrigo (PRGO +1.7%), this one aimed at the development, manufacture and commercialization of two new generic antibiotic foams.
Consistent with earlier deals, SLGL will pursue regulatory approval in the U.S. If successful, PRGO will commercialize. The companies will share development costs and gross profits.
Specific financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.